CENTYL

Main information

  • Trade name:
  • CENTYL Tablets 2.5 Milligram
  • Dosage:
  • 2.5 Milligram
  • Pharmaceutical form:
  • Tablets
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CENTYL Tablets 2.5 Milligram
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0046/018/001
  • Authorization date:
  • 01-04-1978
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

IRISHMEDICINESBOARDACTS1995AND2006

MEDICINALPRODUCTS(CONTROLOFPLACINGONTHEMARKET)REGULATIONS,2007

(S.I.No.540of2007)

PA0046/018/001

CaseNo:2052909

TheIrishMedicinesBoardinexerciseofthepowersconferredonitbytheabovementionedRegulationsherebygrantsto

LeoLaboratoriesLimited

CashelRoad,Dublin12,Ireland

anauthorisation,subjecttotheprovisionsofthesaidRegulations,inrespectoftheproduct

Centyl2.5mgTablets

TheparticularsofwhicharesetoutinPartIandPartIIoftheattachedSchedule.Theauthorisationisalsosubjecttothegeneralconditionsas

maybespecifiedinthesaidRegulationsaslistedonthereverseofthisdocument.

Thisauthorisation,unlesspreviouslyrevoked,shallcontinueinforcefrom18/07/2008.

SignedonbehalfoftheIrishMedicinesBoardthis

________________

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 1

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Centyl2.5mgTablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains2.5mgofbendroflumethiazide.

Excipients:Lactosemonohydrate

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Tablet.

White,circular,flat,slightlybevelledtablet.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Asadiureticinthemanagementofoedemasuchasthatwhicharisesfromcardiac,renalandhepaticorigin.

Inthemanagementofhypertensionaloneorincombinationwithotherantihypertensives.

4.2Posologyandmethodofadministration

Adults:

Oedema

Theusualinitialdoseis2.5to10mgasasingledose,withamaintenancedosageof2.5to5mgdaily,preferablyinthe

morning.

Hypertension

2.5to5mgoncedaily.

4.3Contraindications

Hypersensitivitytotheactivesubstanceoranyoftheexcipients.

Severeelectrolyteimbalanceincludinghypercalcaemia,hyperchloraemiaorhypokalaemia.

Severerenalimpairment.

Severehepaticimpairment.

Addison’sdisease.

Establishedgout.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 2

4.4Specialwarningsandprecautionsforuse

Considerationsshouldbegiventofluidandelectrolytestatustoavoidinadequatepotassiumsupplementationor

excessivelossoffluidespeciallyinelderlypatients.Concomitantmedicationshouldalsobeconsidered.

Bendroflumethiazidemayprovokehyperglycaemiaandglycosuriaindiabeticandothersusceptiblepatients.Incaseof

reducedglucosetolerance,adjustmentsofanti-diabeticmedicinesmaybenecessary.

Thiazidediureticsshouldbeusedwithcautioninpatientswithrenalorhepaticimpairmentandinpatientswith

potentialobstructionoftheurinarytractorwithdisordersrenderingtheirelectrolytebalanceprecarious.

Thiazidesmaycausehyperuricaemiaandprecipitateoraggravateattacksofgout.

Bendroflumethiazidemaycauseexacerbationoractivatingofsystemiclupuserythematous.

Bendroflumethiazidefoundinurinebydopingtestiscausefordisqualificationofathletes.

Patientswithrarehereditaryproblemsofgalactoseintolerance,theLapplactosedeficiencyorglucose-galactose

malabsorptionshouldnottakethismedicine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Theconcomitantadministrationofthispreparationwithcardiacglycosidesorhypotensiveagentsmaynecessitate

adjustmentofthedosageofthosedrugs.

Bendroflumethiazidemaypotentiatetheeffectofantihypertensiveagentsanddrugsinducingposturalhypotensione.g.

tricyclicantidepressants.

Bendroflumethiazidemayimpaircontrolbyhypoglycaemicagentsincasesofdiabetesmellitus(c.f.section4.4).

Non-steroidalanti-inflammatorydrugs(NSAID)inhibittheeffectofbendroflumethiazide.

Bendroflumethiazidereduceslithiumclearanceresultinginhighserumlevelsoflithium;thereforeconcurrentuseis

contraindicated(c.f.section4.3).

Probenecidinhibitstherenaltubularsecretionofbendroflumethiazideleadingtoadiminishednatriuresis.

Cholestyramineandsimilardrugsreducestheabsorptionofthiazides.

Co-administrationofbendroflumethiazideandotherdrugsknowntocausephotosensitivityreactionsmayincrease

theseverityofthesereactions.

Hypokalaemia(whichmaybeinducedbybendroflumethiazide)increasesthesensitivitytodigitalisglycosidesand

non-depolarisingneuromuscularblockingagents.

Theurinaryexcretionofcalciumisreduced.

4.6Pregnancyandlactation

Animalstudiesareinsufficientwithrespecttoeffectsonpregnancy.Thepotentialriskforhumansisunknown.

Bendroflumethiazideshouldnotbeusedduringpregnancyunlessclearlynecessary.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 3

4.7Effectsonabilitytodriveandusemachines

Bendroflumethiazidehasnoornegligibleinfluenceontheabilitytodriveandusemachines.

4.8Undesirableeffects

Themostfrequentundesirableeffectsareheadache,dizziness,fatigue,posturalhypotensionandgastrointestinal

symptoms.Electrolytedisturbancescanoccurespeciallyduringlongtermtreatment.

Thiazidediureticsmaycauseanumberofmetabolicdisturbancesincludingreducedglucosetoleranceand

hyperuricaemia.Musclecramps,variousskinreactions,photosensitivityreactionsanderectiledysfunctionareless

frequent.Vasculitis,blooddyscrasias,mainlyaffectingtheplateletsandacutepancreatitis,havealsobeenreported.

BasedontheclinicaltrialdataforCentyl®Kundesirableeffectsoccurredinapproximately15%andaredose

dependant.

Basedonpost-marketingdataforbothCentyl®andCentyl®K,thetotal“reportingrate”ofundesirableeffectsisvery

rarebeingapproximately2:100,000treatmentmonths.

TheundesirableeffectsarelistedbyMedDRASOCandtheindividualundesirableeffectsarelistedstartingwiththe

mostfrequentlyreported.

Nervoussystemdisorders

Headache

Dizziness

Vertigo

Syncope

Posturalhypotension

Generaldisordersandapplicationsiteconditions

Fatigue

Asthenia

Drymouth

Thirst

Paraesthesia

Gastrointestinaldisorders

Nausea

Gastricirritation

Vomiting

Diarrhoea

Constipation

Metabolismandnutritiondisorder

Dehydration

Hyponatraemia

Hypokalaemia

Gout

Hyperuricaemia

Hyperglycaemia

DiabetesMellitus

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 4

Hypochloraemia

Hypocalcaemia

Hypomagnesaemia

Musculoskeletalandconnectivetissuedisorders

Myalgia

Musclecramp

Skinandsubcutaneoustissuereactions:

Rash

Photosensitivityreactions

Pruritus

Reproductiveandbreastdisorder

Erectiledysfunction

VascularDisorders

Hypotension

Vasculitis

Bloodandlymphaticsystemdisorder

Thrombocytopenia

Granulocytopenia

4.9Overdose

Inhighdosesthiazidediureticsmaycauseelectrolyteimbalance,dehydrationandpolyuria.

Symptomsofelectrolyteimbalanceincludedrymouth,thirst,weakness,lethargy,drowsiness,gastrointestinal

disturbances,restlessness,musclepainandcramps,andseizures.

Treatmentisadjustmentofthefluidandelectrolyteimbalance.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

ATCCode:C03AA01

Bendroflumethiazideisathiazidediureticwhichactsonbothdeterminantsofhypertension,i.e.cardiacoutputand

peripheralresistance.Cardiacoutputisreducedduetothedecreaseinbloodvolumeresultingfromthediureticeffect.

Centylreducesperipheralresistancebyavasodilatingeffect,themechanismofwhichisnotcompletelyunderstood.

Inoedematousconditionsthediureticactionreducesextravascularfluidvolume.

5.2Pharmacokineticproperties

Bendroflumethiazidehasbeenreportedtobecompletelyabsorbedfromthegastrointestinaltractandtohaveahalf-life

ofabout3or4hours.Plasmaproteinbinding,aswithmostthiazides,ishigh.Thereisevidencethat

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 5

5.3Preclinicalsafetydata

Therearenopre-clinicaldataofrelevancetotheprescriberwhichareadditionaltothatalreadyincludedinother

sectionsoftheSPC.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Colloidalanhydroussilica

Gelatin

Maizestarch

Lactosemonohydrate

Talc

Magnesiumstearate

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

2years.

6.4Specialprecautionsforstorage

Donotstoreabove25 °

6.5Natureandcontentsofcontainer

Amberglassbottlesof100and500tablets.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Medicinesshouldnotbedisposedofviawastewaterofhouseholdwaste.Askyourpharmacisthowtodisposeof

medicinesnolongerrequired.Thesemeasureswillhelptoprotecttheenvironment.

7MARKETINGAUTHORISATIONHOLDER

LEOLaboratoriesLimited

285CashelRoad

Dublin12

8MARKETINGAUTHORISATIONNUMBER

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 6

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:01April1978

Dateoflastrenewal:14thNovember2007

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 23/07/2008 CRN 2052909 page number: 7